Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: A current understanding

European Respiratory Journal

Volumn 41, Issue 2, 2013, Pages 462-468

  Lang, Irene M ^a   Pesavento, Raffaele ^b   Bonderman, Diana ^a   Yuan, Jason X J ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Chronic thromboembolic pulmonary hypertension; Coagulation; Review; Vascular biology

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRINOGEN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DISEASE MODEL; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE; FIBRINOLYSIS; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY; RECURRENT DISEASE; RISK FACTOR; STEM CELL; THROMBOCYTE COUNT; THROMBOSIS;

ANIMALS; BIOPSY; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; FIBRINOGEN; FIBRINOLYSIS; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; PULMONARY ARTERY; PULMONARY EMBOLISM; RISK FACTORS; THROMBOEMBOLISM;

EID: 84873360105     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00049312     Document Type: Article

References (68)

1. Lang IM. Chronic thromboembolic pulmonary hypertension-not so rare after all. N Engl J Med 2004; 350: 2236-2238.
2. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465-1472.
3. Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006; 130: 172-175.
4. Benotti JR, Ockene IS, Alpert JS, et al. The clinical profile of unresolved pulmonary embolism. Chest 1983; 84: 669-678.
5. Klok FA, van Kralingen KW, van Dijk AP, et al. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 2010; 95: 970-975.
6. Miniati M, Monti S, Bottai M, et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore) 2006; 85: 253-262.
7. Ribeiro A, Lindmarker P, Johnsson H, et al. Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation 1999; 99: 1325-1330.
8. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
9. Dentali F, Donadini M, Gianni M, et al. Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 2009; 124: 256-258.
10. Surie S, Gibson NS, Gerdes VE, et al. Active search for chronic thromboembolic pulmonary hypertension does not appear indicated after acute pulmonary embolism. Thromb Res 2010; 125: e202-e205.
11. Marti D, Gomez V, Escobar C, et al. Incidencia de hipertensión pulmonar tromboembó lica crónica sintomática y asintomática [Incidence of symptomatic and asymptomatic chronic thromboembolic pulmonary hypertension]. Arch Broncopneumol 2010; 46: 628-633.
12. Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23: 637-648.
13. Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 1990; 81: 1735-1743.
14. Bernard J, Yi ES. Pulmonary thromboendarterectomy: A clinicopathologic study of 200 consecutive pulmonary thromboendarterectomy cases in one institution. Hum Pathol 2007; 38: 871-877.
15. Blauwet LA, Edwards WD, Tazelaar HD, et al. Surgical pathology of pulmonary thromboendarterectomy: A study of 54 cases from 1990 to 2001. Hum Pathol 2003; 34: 1290-1298.
16. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124: 1973-1981.
17. Bonderman D, Turecek PL, Jakowitsch J, et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003; 90: 372-376.
18. Wolf M, Boyer-Neumann C, Parent F, et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000; 15: 395-399.
19. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76: 1457-1462.
20. Riedel M, Stanek V, Widimsky J, et al. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 1982; 81: 151-158.
21. Bonderman D, Jakowitsch J, Adlbrecht C, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93: 512-516.
22. Wong CL, Szydlo R, Gibbs S, et al. Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis 2010; 21: 201-206.
23. Laczika K, Lang IM, Quehenberger P, et al. Unilateral chronic thromboembolic pulmonary disease associated with combined inherited thrombophilia. Chest 2002; 121: 286-289.
24. Auger WR, Permpikul P, Moser KM. Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: A preliminary report. Am J Med 1995; 99: 392-396.
25. Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009; 33: 325-331.
26. Quarck R, Nawrot T, Meyns B, et al. C-reactive protein: A new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 1211-1218.
27. Wynants M, Quarck R, Ronisz A, et al. Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension. Eur Respir J 2012; 40: 886-894.
28. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-242.
29. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: A multicenter prospective study. Blood 2011; 118: 4714-4718.
30. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782-2784.
31. Poli D, Grifoni E, Antonucci E, et al. Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. J Thromb Thrombolysis 2010; 30: 294-299.
32. Auger WR, Fedullo PF. Chronic thromboembolic pulmonary hypertension. Semin Respir Crit Care Med 2009; 30: 471-483.
33. Grifoni S, Vanni S, Magazzini S, et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med 2006; 166: 2151-2156.
34. Olman MA, Marsh JJ, Lang IM, et al. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation 1992; 86: 1241-1248.
35. Prandoni P, Prins MH, Lensing AW, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: A randomized trial. Ann Intern Med 2009; 150: 577-585.
36. Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertensionLimitations of the embolic hypothesis. Eur Respir J 2000; 15: 440-448.
37. Bonderman D, Skoro-Sajer N, Jakowitsch J, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007; 115: 2153-2158.
38. Natali D, Jais X, Abraham M, et al. Chronic thromboembolic pulmonary hypertension associated with indwelling Port-A-Cath1 central venous access systems. Am J Respir Crit Care Med 2011; 183: A2409.
39. Langer F, Schramm R, Bauer M, et al. Cytokine response to pulmonary thromboendarterectomy. Chest 2004; 126: 135-141.
40. Kimura H, Okada O, Tanabe N, et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2001; 164: 319-324.
41. Distler JH, Hirth A, Kurowska-Stolarska M, et al. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003; 47: 149-161.
42. Waltham M, Burnand KG, Collins M, et al. Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi. J Vasc Surg 2000; 32: 988-996.
43. Firth AL, Yao W, Ogawa A, et al. Multipotent mesenchymal progenitor cells are present in endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Cell Physiol 2010; 298: C1217-C1225.
44. Sakao S, Hao H, Tanabe N, et al. Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells. Respir Res 2011; 12: 109.
45. Henke PK, Wakefield TW, Kadell AM, et al. Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res 2001; 99: 84-91.
46. Waltham M, Burnand KG, Collins M, et al. Vascular endothelial growth factor enhances venous thrombus recanalisation and organisation. Thromb Haemost 2003; 89: 169-176.
47. Varma MR, Moaveni DM, Dewyer NA, et al. Deep vein thrombosis resolution is not accelerated with increased neovascularization. J Vasc Surg 2004; 40: 536-542.
48. Evans CE,Humphries J,Waltham M, et al. Upregulation of hypoxiainducible factor 1a in local vein wall is associated with enhanced venous thrombus resolution. Thromb Res 2011; 128: 346-351.
49. Morris TA, Marsh JJ, Chiles PG, et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009; 114: 1929-1936.
50. Miniati M, Fiorillo C, Becatti M, et al. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med 2010; 181: 992-996.
51. Morris TA, Marsh JJ, Chiles PG, et al. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 2006; 173: 1270-1275.
52. Suntharalingam J, Goldsmith K, van Marion V, et al. Fibrinogen Aa Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. Eur Respir J 2008; 31: 736-741.
53. Le Gal G, Delahousse B, Lacut K, et al. Fibrinogen Aa-Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolism. Thromb Res 2007; 121: 333-338.
54. Lang IM, Marsh JJ, Konopka RG, et al. Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation 1993; 87: 1990-2000.
55. Marsh JJ, Konopka RG, Lang IM, et al. Suppression of thrombolysis in a canine model of pulmonary embolism. Circulation 1994; 90: 3091-3097.
56. Mercier O, Tivane A, Raoux F, et al. A reliable piglet model of chronic thrombo-embolic pulmonary hypertension. Am J Resp Crit Care Med 2011; 183: A2415.
57. Bonderman D, Jakowitsch J, Redwan B, et al. Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2008; 28: 678-684.
58. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993; 103: 685-692.
59. Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007; 5: 483-489.
60. Lang IM, Marsh JJ, Olman MA, et al. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994; 89: 2715-2721.
61. Lang IM, Marsh JJ, Olman MA, et al. Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation 1994; 90: 706-712.
62. Galie N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006; 3: 571-576.
63. Skoro-Sajer N, Hack N, Sadushi-Kolici R, et al. Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: A pilot study. Circulation 2009; 119: 298-305.
64. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest 2007; 117: 530-538.
65. Arbustini E, Morbini P, D'Armini AM, et al. Plaque composition in plexogenic and thromboembolic pulmonary hypertension: the critical role of thrombotic material in pultaceous core formation. Heart 2002; 88: 177-182.
66. Maruoka M, Sakao S, Kantake M, et al. Characterization of myofibroblasts in chronic thromboembolic pulmonary hypertension. Int J Cardiol 2011; 159: 119-127.
67. Quarck R, Wynants M, Ronisz A, et al. Characterization of proximal pulmonary arterial cells from chronic thromboembolic pulmonary hypertension patients. Respir Res 2012; 13: 27.
68. YaoW, Firth AL, Sacks RS, et al. Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2009; 296: L870-L878.